RECURRENT RENAL PELVIS UROTHELIAL CARCINOMA
Clinical trials for RECURRENT RENAL PELVIS UROTHELIAL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT RENAL PELVIS UROTHELIAL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT RENAL PELVIS UROTHELIAL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo aims to fight tough bladder cancer
Disease control OngoingThis study tests whether adding the chemotherapy drug eribulin to the immunotherapy atezolizumab works better than atezolizumab alone for people with advanced or spreading bladder cancer who cannot take standard cisplatin chemo. About 72 adults with recurrent or metastatic urothe…
Matched conditions: RECURRENT RENAL PELVIS UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New drug cocktail targets Hard-to-Treat bladder cancer
Disease control OngoingThis early-phase trial is testing a combination of two drugs—erdafitinib and enfortumab vedotin—in 24 people with advanced bladder cancer that has spread and has specific FGFR2/3 gene changes. Erdafitinib blocks a faulty protein that helps cancer grow, while enfortumab vedotin de…
Matched conditions: RECURRENT RENAL PELVIS UROTHELIAL CARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Can a gene test tell who responds to immunotherapy for bladder cancer?
Knowledge-focused OngoingThis small phase II trial is studying whether specific gene mutations (ARID1A and KDM6A) and a protein called CXCL13 can predict how well patients with advanced bladder cancer respond to the immunotherapy drug nivolumab. Six participants with metastatic urothelial cancer whose tu…
Matched conditions: RECURRENT RENAL PELVIS UROTHELIAL CARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC